We are live on
!
Find out more
Qube Research & Technologies (QRT) Portfolio holdings
AUM
$89.9B
1-Year Est. Return
20.22%
This Fund
S&P 500
This Quarter
Est. Return
+6.68%
1 Year Est. Return
+20.22%
3 Year Est. Return
+42.42%
5 Year Est. Return
+23.97%
10 Year Est. Return
–
AUM
$18.7B
AUM Growth
+$1.89B
(+11%)
Cap. Flow
+$1.31B
Cap. Flow
% of AUM
7.02%
Top 10 Holdings %
Top 10 Hldgs %
10.01%
Holding
3,237
New
779
Increased
845
Reduced
690
Closed
834
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$109M |
| 2 |
Norwegian Cruise Line
NCLH
|
+$105M |
| 3 |
Goldman Sachs
GS
|
+$104M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
+$101M |
| 5 |
Steel Dynamics
STLD
|
+$99.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Chevron
CVX
|
+$176M |
| 2 |
Coca-Cola
KO
|
+$151M |
| 3 |
Broadcom
AVGO
|
+$146M |
| 4 |
Microsoft
MSFT
|
+$140M |
| 5 |
ExxonMobil
XOM
|
+$137M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 16.93% |
| 2 | Industrials | 11.65% |
| 3 | Consumer Discretionary | 11.56% |
| 4 | Healthcare | 11.56% |
| 5 | Financials | 11.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1426
Vanguard FTSE Pacific ETF
VPL
$7.89B
| $582K | ﹤0.01% |
+9,048
| New | +$564K |
|
1427
Badger Meter
BMI
$3.9B
| $578K | ﹤0.01% |
+5,302
| New | +$576K |
|
|
CBAY
1428
DELISTED
Cymabay Therapeutics
CBAY
| $577K | ﹤0.01% |
92,105
+32,081
| +53% | +$122K |
|
1429
First Trust Value Line Dividend Fund
FVD
$8.46B
| $576K | ﹤0.01% |
+14,429
| New | +$563K |
|
1430
Arcosa
ACA
$7.13B
| $573K | ﹤0.01% |
10,542
-12,397
| -54% | -$736K |
|
1431
Qiagen
QGEN
$8.72B
| $567K | ﹤0.01% |
10,728
-520,093
| -98% | -$25.6M |
|
1432
iShares MSCI South Africa ETF
EZA
$533M
| $566K | ﹤0.01% |
13,352
-98,040
| -88% | -$4.01M |
|
1433
Helix Energy Solutions
HLX
$1.35B
| $561K | ﹤0.01% |
+76,046
| New | +$457K |
|
1434
Ameris Bancorp
ABCB
$5.9B
| $558K | ﹤0.01% |
+11,831
| New | +$592K |
|
1435
Vanguard Financials ETF
VFH
$13.6B
| $553K | ﹤0.01% |
6,680
+1,129
| +20% | +$93.3K |
|
1436
Wolfspeed
WOLF
$1.14B
| $548K | ﹤0.01% |
+7,942
| New | +$704K |
|
|
GDEN
1437
DELISTED
Golden Entertainment
GDEN
| $548K | ﹤0.01% |
14,640
+7,982
| +120% | +$329K |
|
1438
BlackRock Health Sciences Trust II
BMEZ
$968M
| $546K | ﹤0.01% |
35,354
| – | – |
|
1439
Oscar Health
OSCR
$9.47B
| $543K | ﹤0.01% |
+220,576
| New | +$689K |
|
1440
City Holding Co
CHCO
$2.04B
| $541K | ﹤0.01% |
5,814
+3,063
| +111% | +$295K |
|
1441
La-Z-Boy
LZB
$1.65B
| $541K | ﹤0.01% |
23,715
-4,157
| -15% | -$101K |
|
|
SJT
1442
San Juan Basin Royalty Trust
SJT
$117M
| $540K | ﹤0.01% |
47,260
-16,526
| -26% | -$181K |
|
|
AMPS
1443
DELISTED
Altus Power
AMPS
| $539K | ﹤0.01% |
+82,697
| New | +$675K |
|
1444
ePlus
PLUS
$2.42B
| $538K | ﹤0.01% |
+12,141
| New | +$566K |
|
1445
iShare MSCI Eurozone ETF
EZU
$9.44B
| $537K | ﹤0.01% |
13,605
+12,813
| +1,618% | +$479K |
|
|
SPNS
1446
DELISTED
Sapiens International
SPNS
| $536K | ﹤0.01% |
29,028
-8,745
| -23% | -$165K |
|
1447
Amplify Junior Silver Miners ETF
SILJ
$3.19B
| $535K | ﹤0.01% |
+50,742
| New | +$513K |
|
1448
iShares MSCI Sweden ETF
EWD
$536M
| $533K | ﹤0.01% |
16,501
-1,165
| -7% | -$36.4K |
|
|
CAN
1449
Canaan Creative
CAN
$178M
| $529K | ﹤0.01% |
256,850
+118,855
| +86% | +$329K |
|
1450
Xencor
XNCR
$1.48B
| $528K | ﹤0.01% |
20,281
+11,835
| +140% | +$331K |
|
Similar funds
Qube Research & Technologies (QRT)'s Q4 2022 Portfolio in Review
As of Q4 2022, Qube Research & Technologies (QRT) held 3,237 positions worth $18.7B, up 11% from $16.8B the previous quarter. Its ten largest holdings account for 10% of the portfolio.
Qube Research & Technologies (QRT) deployed $1.31B of net new capital in Q4 2022, opening 779 new positions and adding to 845 existing holdings. Its largest new stake was Bristol-Myers Squibb: 1,451,017 shares worth $104M.
By sector, the portfolio is most concentrated in Technology at 17% of assets, down from 21% a quarter earlier, followed by Industrials and Consumer Discretionary.
On the sell side, the largest reduction was Microsoft, an estimated $140M trimmed.
- Qube Research & Technologies (QRT)'s largest Q4 2022 buy was Bristol-Myers Squibb: 1,451,017 shares worth $104M.
- Qube Research & Technologies (QRT) added most to Goldman Sachs in Q4 2022, an estimated $104M increase.
- Qube Research & Technologies (QRT)'s biggest Q4 2022 reduction was Microsoft, cutting an estimated $140M.
- Qube Research & Technologies (QRT) fully exited Chevron in Q4 2022, selling an estimated $176M.
- Qube Research & Technologies (QRT)'s ten largest holdings make up 10% of its $18.7B portfolio in Q4 2022.
- Qube Research & Technologies (QRT) opened 779 new positions and closed 834 in Q4 2022.
- Qube Research & Technologies (QRT)'s portfolio value rose 11% quarter-over-quarter to $18.7B.
Based on Qube Research & Technologies (QRT)'s 13F filing for Q4 2022, filed 14 Feb 2023.